细胞周期停滞生物标志物对重症COVID-19患者急性肾损伤的预测作用:一项多中心观察性研究
这项多中心、前瞻性、观察性研究纳入欧洲和英国12个中心的中重度COVID-19相关ARDS患者,连续检测尿(TIMP-2)×(IGFBP7),主要终点为按KDIGO定义发生中重度急性肾损伤(AKI)。300例患者纳入主要分析,39例达到主要终点。入组时尿(TIMP-2)×(IGFBP7)对主要终点预测的ROC曲线下面积为0.89(95%CI 0.84-0.93),且在终点阳性患者中入组时和12小时时均显著更高。作者认为尿(TIMP-2)×(IGFBP7)可预测重症COVID-19相关ARDS患者AKI的发生。
要点
- 重症COVID-19相关ARDS患者中,入组时尿(TIMP-2)×(IGFBP7)预测中重度AKI的AUC达0.89(95%CI 0.84-0.93)。
- 研究纳入300例中重度COVID-19相关ARDS患者,39例发生主要终点(KDIGO定义的中重度AKI)。
- 终点阳性患者入组时和12小时时的尿(TIMP-2)×(IGFBP7)均显著高于终点阴性患者。
- 该指标为无创尿液检测,可在入组时即提供AKI风险信息。
- 研究设计为多中心、前瞻性、观察性研究,无干预措施。
适用人群与场景
- 欧洲和英国12个中心的重症监护病房中,中重度COVID-19相关ARDS患者。
- 研究未报告排除标准。
诊断标准与关键阈值
- 主要终点为中重度急性肾损伤,采用肾脏病:改善全球预后(KDIGO)定义。
研究设计与关键结果
- 研究类型:多中心、前瞻性、观察性研究,12个中心(欧洲和英国),无干预措施。
- 300例患者纳入主要分析,39例达到主要终点(KDIGO定义的中重度AKI)。
- 入组时尿(TIMP-2)×(IGFBP7)预测主要终点的ROC曲线下面积为0.89(95%CI 0.84-0.93)。
- 终点阳性患者入组时和12小时时尿(TIMP-2)×(IGFBP7)均显著高于终点阴性患者。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为尿(TIMP-2)×(IGFBP7)可预测重症COVID-19相关ARDS患者AKI的发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Patients with COVID-19-associated acute respiratory distress syndrome (ARDS) have a high risk for developing acute kidney injury (AKI) which is associated with an increased risk of death and persistent renal failure. Early prediction of AKI is crucial in order to implement preventive strategies. The purpose of this study was to investigate the predictive performance of tissue inhibitor of metalloproteinases 2 and insulin like growth factor binding protein 7 (TIMP-2) × (IGFBP7) in critically ill patients with COVID-19-associated ARDS.
DESIGN: Multicenter, prospective, observational study.
SETTING: Twelve centers across Europe and United Kingdom.
PATIENTS: Patients with moderate or severe COVID-19-associated ARDS were included and serial measurements of (TIMP-2) × (IGFBP7) were performed.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the development of moderate or severe AKI according to the Kidney Disease: Improving Global Outcomes definition. Three hundred patients were available for the primary analysis, and 39 met the primary endpoint. At enrollment, urinary (TIMP-2) × (IGFBP7) had high predictive value for the primary endpoint with an area under the receiver operating characteristic curve of 0.89 (95% CI, 0.84-0.93). (TIMP-2) × (IGFBP7) was significantly higher in endpoint-positive patients at enrollment and at 12 hours.
CONCLUSIONS: Urinary (TIMP-2) × (IGFBP7) predicts the occurrence of AKI in critically ill patients with COVID-19-associated ARDS.
参考来源
- Weiss R, von Groote T, Ostermann M, et al. The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study. Crit Care Med. 2023. PMID: 36975308. doi:10.1097/CCM.0000000000005853
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。